Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase 1/2 Trial of Abemaciclib + Avutometinib (VS-6766) + Fulvestrant in Metastatic HR+/HER2- Breast Cancer

NCT05608252 is registered in ClinicalTrials.gov with Adrienne G. Waks as lead sponsor.

NCT NCT05608252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05608252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase 1/2 Trial of Abemaciclib + Avutometinib (VS-6766) + Fulvestrant in Metastatic HR+/HER2- Breast Cancer
Lead sponsor
Adrienne G. Waks
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2023
Completion date
December 31, 2028
Enrollment
63 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive her-2 negative breast cancer, hormone receptor-positive breast cancer